Answers are grounded in this paper and cite their sources.
D URING the past decade there have been important developments in the treatment of patients with skull-base tumors. Many factors have contributed to these advances including improved diagnosis with magnetic resonance imaging, advances in interventional neuroradiology, the application of microsurgieal techniques, the development of the team concept with cooperation of neurosurgeon, otolaryngologist, and plastic surgeon during surgery, improved postoperative care, and the cooperation of the radiation therapist and neurosurgeon in planning radiosurgery. We now have journals and societies specializing in the skull base, and the topic is included in the programs of most neurosurgical meetings. The development and use of these technical accomplishments for skull-base tumors impose a major responsibility on physicians caring for these patients. It is imperative that the physician carefully consider what is the best treatment option to recommend to a patient with a skull-base tumor. Should the patient have surgery, radiation therapy, a combination of therapies, or no specific treatment but careful follow-up monitoring with periodic scans and clinical evaluations7 Should surgery be a biopsy, subtotal removal, or a plan for complete removal which may include endovascular treatment and multiple procedures? If radiosurgery is to be part of the treatment program, should it be conventional fractionated therapy, gamma knife, linear acceleration, or proton beam using single-dose or fractional techniques? If the patient is to be followed, how often should the re-evaluation be performed? How does the physician choose from among these options the treatment program best suited to the individual patient? Initially, the physician should take the patient's history directly and not rely on the interpretation of someone else's notes. A first-hand account of the symptoms, what the course of those symptoms has been, and how those symptoms are affecting the patient's life should be obtained. There should be an objective assessment of any neurological deficit. Radiographic studies should be carefully reviewed to be sure they are adequate and to decide if any additional studies are needed. Having acquired this information, the treatment options can be considered. In some patients there is little doubt as to what should be done and the physician readily settles on the best option. However, in many patients the decision may be difficult. ~ How does one come to a decision? The physician must have up-todate knowledge about both the natural history and the treatment alternatives if the patient is to receive the best advice. This means regular reading of appropriate books and journals, attendance at postgraduate courses, lectures, and the annual meetings of our national societies, the use of audio and video tapes, computer searches of the literature, and discussions with informed colleagues. With this background information, one can begin to weigh a specific treatment option against whatever knowledge one possesses or thinks one possesses about the natural history of the illness. Unfortunately, much of our knowledge about the natural history may be anecdotal and subjective. Then one needs to consider the impact of the treatment option on the patient's life utilizing one's knowledge, or at least one's impression, as to what are the immediate and long-term results of the treatment being recommended. Will any treatment improve the symptoms? What is the chance that further progression or recurrence of the tumor can be prevented? What are the risks of the treatment? Do the potential long-term benefits justify these risks? It is important to discuss with the patients their own hopes and expectations from the treatment program. In this issue of the Journal of Neurosurgery, Dr. Sekhar and his colleagues report their experiences with the surgical management of 20 patients with temporal bone neoplasms.7 This group has been one of the leaders in applying microsurgical techniques to skull-base lesions previously thought to be inoperable. AI-Mefty ~
No takes yet. Share an insight, caveat, or question.
Robert G. Ojemann (1992) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: